Trial Search Results

Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SQ3370 in patients with cancer (solid tumors).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Shasqi, Inc.

Stanford Investigator(s):


  • Drug: SQ3370


Phase 1


Inclusion Criteria:

   - Diagnosis of an advanced local or metastatic solid tumor

   - Adequate hematologic, hepatic, renal, and coagulation function

   - Tumor is a type where published clinical data would suggest is responsive to

Exclusion Criteria:

   - Prior exposure to 225 mg/m^2 of Dox HCl or DOXIL / CAELYX ® or 450 mg/m^2 of
   epirubicin HCl.

   - CHF, severe myocardial insufficiency, or cardiac arrhythmia

   - Any of the following within 28 days prior to Cycle 1 Day 1:

      - Major surgery, as defined by the Investigator

      - Radiotherapy

      - Chemotherapy (except for small molecule kinase inhibitors, which are 6
      elimination half-lives)

      - Currently enrolled in or discontinued from a clinical study involving an
      investigational agent or non-approved use of a drug or device, or concurrently
      enrolled in any other type of medical research judged not to be scientifically or
      medically compatible with this study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Behnaz P Agahian